Natural products have been implemented in medicine through use as herbal medications, chemical compound extraction for prescription medication, or a natural source of food to fight various infections and diseases. Gen...Natural products have been implemented in medicine through use as herbal medications, chemical compound extraction for prescription medication, or a natural source of food to fight various infections and diseases. Genetics has played a role in identifying various interactions between existing drugs and side effects. In addition, various food allergies have been identified with children in recent years, suggesting genetic associations between certain populations carrying specific genetic alleles. The recent availability of genomic data and our increased understanding of the effects of genetic variations permit a quantitative examination of the contribution of genetic variation to efficacy or toxicity of compounds derived from natural sources. The identification of target molecules relevant for diseases allows screening for natural products capable of inhibiting targets which can lead to the development of rational treatment of various diseases including neurobiological disorders, cancer, osteoporosis, and cardiovascular diseases. This allows for more opportunities to predict the response of individual patients. Identification of genetic variations that arose as a consequence of naturally occurring compounds will help identify gene alleles, or protein ligands that can affect the pharmacodynamic and pharmacokinetics of the natural products in question. In addition, diet modification and precautions to food products can be identified to help consumers limit or increase certain food intake. Understanding the molecular mechanisms underlying these interactions and their modification by genetic variation is expected to result in the development of new drugs that optimize individual health. We expect that strategies for individualized therapies will lead to improved results for patients.展开更多
Dear Editor, I would like to offer some comments on the excellent article by Hai-Yan He and colleagues published in Genomics, Proteomics ＆ Bioinformatics on 1st April 2017 [1]. The authors include, in the list of gen...Dear Editor, I would like to offer some comments on the excellent article by Hai-Yan He and colleagues published in Genomics, Proteomics ＆ Bioinformatics on 1st April 2017 [1]. The authors include, in the list of genetic polymorphisms that have an effect on vita- mins, the low concentrations of cellular and plasma vitamin B12 in GG carriers of SNP rs602662 （772 G 〉 A） in the gene encoding fucosyltransferase 2 （FUT2）.展开更多
Dear Editor, We thank the author for making meaningful comments on our recent article [1]. The SNP 772G 〉 A （rs602662） in exon 2 of the gene encoding fucosyl transferase （FUT2） has been found to be related with t...Dear Editor, We thank the author for making meaningful comments on our recent article [1]. The SNP 772G 〉 A （rs602662） in exon 2 of the gene encoding fucosyl transferase （FUT2） has been found to be related with the alterations in plasma vitamin B12 levels. GG carriers possessed lower levels of vitamin B12. However, we didn＇t know the mechanism behind this association.展开更多
Vitamins are vital to sustain normal physiological function, metabolism, and growth for all living organisms. Being an integral component of coenzyme, vitamins can affect the catalytic activities of many enzymes and t...Vitamins are vital to sustain normal physiological function, metabolism, and growth for all living organisms. Being an integral component of coenzyme, vitamins can affect the catalytic activities of many enzymes and the expression of drug transporters. Genetic variations in metabolism and/or transporter genes of drugs can influence the exposure of the human body to drugs and/or their active metabolites, thus contributing to the variations in drug responses and toxicities.Nonetheless, pharmacogenomics studies on nutrients have been rarely summarized. In this article,we reviewed recent progress on vitamin pharmacogenomics, for a better understanding on the influence of vitamin-related gene polymorphisms on inter-individual differences in diseases and drug efficacy and safety.展开更多
文摘Natural products have been implemented in medicine through use as herbal medications, chemical compound extraction for prescription medication, or a natural source of food to fight various infections and diseases. Genetics has played a role in identifying various interactions between existing drugs and side effects. In addition, various food allergies have been identified with children in recent years, suggesting genetic associations between certain populations carrying specific genetic alleles. The recent availability of genomic data and our increased understanding of the effects of genetic variations permit a quantitative examination of the contribution of genetic variation to efficacy or toxicity of compounds derived from natural sources. The identification of target molecules relevant for diseases allows screening for natural products capable of inhibiting targets which can lead to the development of rational treatment of various diseases including neurobiological disorders, cancer, osteoporosis, and cardiovascular diseases. This allows for more opportunities to predict the response of individual patients. Identification of genetic variations that arose as a consequence of naturally occurring compounds will help identify gene alleles, or protein ligands that can affect the pharmacodynamic and pharmacokinetics of the natural products in question. In addition, diet modification and precautions to food products can be identified to help consumers limit or increase certain food intake. Understanding the molecular mechanisms underlying these interactions and their modification by genetic variation is expected to result in the development of new drugs that optimize individual health. We expect that strategies for individualized therapies will lead to improved results for patients.
文摘Dear Editor, I would like to offer some comments on the excellent article by Hai-Yan He and colleagues published in Genomics, Proteomics ＆ Bioinformatics on 1st April 2017 [1]. The authors include, in the list of genetic polymorphisms that have an effect on vita- mins, the low concentrations of cellular and plasma vitamin B12 in GG carriers of SNP rs602662 （772 G 〉 A） in the gene encoding fucosyltransferase 2 （FUT2）.
基金supported by grants from the National Key Research and Development Program(Grant No.2016YFC0905000)National High-tech R&D Program of China(863 Program+2 种基金Grant No.2012AA02A518)National Natural Scientific Foundation of China(Grant Nos.81522048,81573511,81273595)the Innovation-driven Project of Central South University,China(Grant No.2016CX024)
文摘Dear Editor, We thank the author for making meaningful comments on our recent article [1]. The SNP 772G 〉 A （rs602662） in exon 2 of the gene encoding fucosyl transferase （FUT2） has been found to be related with the alterations in plasma vitamin B12 levels. GG carriers possessed lower levels of vitamin B12. However, we didn＇t know the mechanism behind this association.
基金supported by grants from the National Key Research and Development Program (Grant No. 2016YFC0905000)National High-tech R&D Program of China (863 Program+2 种基金 Grant No. 2012AA02A518)National Natural Scientific Foundation of China (Grant Nos. 81522048, 81573511, and 81273595)the Innovationdriven Project of Central South University, China (Grant No. 2016CX024)
文摘Vitamins are vital to sustain normal physiological function, metabolism, and growth for all living organisms. Being an integral component of coenzyme, vitamins can affect the catalytic activities of many enzymes and the expression of drug transporters. Genetic variations in metabolism and/or transporter genes of drugs can influence the exposure of the human body to drugs and/or their active metabolites, thus contributing to the variations in drug responses and toxicities.Nonetheless, pharmacogenomics studies on nutrients have been rarely summarized. In this article,we reviewed recent progress on vitamin pharmacogenomics, for a better understanding on the influence of vitamin-related gene polymorphisms on inter-individual differences in diseases and drug efficacy and safety.
